Concept Architecture
Concept
Theoretically, Non-Inferiority Trial is a randomised clinical trial designed to demonstrate that the effectiveness of a new intervention is not unacceptably worse than that of an established active comparator by more than a pre-specified non-inferiority margin. The concept is founded on hypothesis testing, confidence interval estimation and clinical trial methodology. It exists to evaluate interventions that may offer advantages such as improved safety, reduced cost, greater convenience or easier administration while maintaining acceptable clinical effectiveness.
Mathematically, Non-Inferiority Trial methodology is based on comparing the estimated treatment difference with a predefined non-inferiority margin (?). Statistical inference is performed using confidence intervals or equivalent one-sided hypothesis tests. Non-inferiority is demonstrated when the lower confidence limit for the treatment difference remains above the non-inferiority margin, indicating that any loss of efficacy is clinically acceptable.
In practice, the non-inferiority margin is established before the trial begins using clinical evidence and regulatory guidance. Participants are randomly allocated to the investigational treatment or an active comparator, and outcomes are analysed using both intention-to-treat and per-protocol populations. The resulting treatment effect estimates are interpreted relative to the predefined margin. Non-inferiority trials are widely used in evaluations of new pharmaceuticals, biosimilars, medical devices and alternative treatment strategies, providing evidence for regulatory approval and health economic evaluation.
Purpose
Used to demonstrate that a new intervention is not clinically unacceptably less effective than an established treatment while potentially offering other clinical, economic or practical advantages.
Mathematical Formulae
Primary Formula
Non-inferiority criterion:
?? ? ?? > ??
where:
- ?? = mean outcome for the investigational treatment
- ?? = mean outcome for the active comparator
- ? = pre-specified non-inferiority margin
Non-inferiority is concluded when the lower confidence limit for (?? ? ??) exceeds ??.
Supporting Formulae
Confidence interval:
CI = (??? ? ???) � t ? SE(??? ? ???)
One-sided hypotheses:
H?: ?? ? ?? � ??
H?: ?? ? ?? > ??
Related Mathematical Methods
- Confidence Interval Estimation
- One-Sided Hypothesis Testing
- Intention-to-Treat Analysis
- Per-Protocol Analysis
- Analysis of Variance
- General Linear Models
- Logistic Regression
Example
A randomised trial compares a once-weekly injectable medicine with a standard daily treatment. The non-inferiority margin is predefined as ?5 percentage points for treatment response. The estimated difference in response rates is ?1.8%, with a 95% confidence interval of ?4.2% to 0.6%.
Because the lower confidence limit (?4.2%) remains above the non-inferiority margin (?5%), the new treatment is concluded to be non-inferior to the standard therapy. Its simpler dosing schedule and comparable effectiveness may subsequently be incorporated into a cost-effectiveness analysis.
Excel Implementation
| Function | Example Formula | Health Economics Application |
|---|---|---|
| AVERAGE | =AVERAGE(B2:B201)-AVERAGE(C2:C201) | Calculate the estimated treatment difference. |
| CONFIDENCE.T | =CONFIDENCE.T(0.05,SD,N) | Calculate the confidence interval half-width. |
| IF | =IF(LowerCI>-Margin,"Non-Inferior","Not Demonstrated") | Determine whether non-inferiority has been established. |
| STDEV.S | =STDEV.S(B2:B201) | Estimate outcome variability. |
| T.TEST | =T.TEST(B2:B201,C2:C201,2,2) | Perform supporting statistical comparisons. |
VBA (Optional)
VBA can automate non-inferiority analyses by calculating treatment differences, confidence intervals and predefined margin assessments for regulatory reporting.
Sources
- Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW. Reporting of Noninferiority and Equivalence Randomized Trials: Extension of the CONSORT Statement.
- ICH E9. Statistical Principles for Clinical Trials.
- FDA. Non-Inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry.
- EMA. Guideline on the Choice of the Non-Inferiority Margin.
- Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. Fundamentals of Clinical Trials.
- NICE. Health Technology Evaluation Manual.
Related Concepts (2)
Library
Publications
1
Economic Evaluation in Clinical Trials — Glick, Doshi, Sonnad & Polsky, 2nd Edition ed., 2015 (Oxford University Press)
Practical guidance on conducting cost-effectiveness analyses alongside controlled trials, covering trial design, measurement of costs and quality-adjusted life years, handling censored and missing data, and reporting stochastic uncertainty. Volume 4 in the Handbooks in Health Economic Evaluation series.
BookView source →
Frequently Asked Questions (7)
What is a non inferiority trial?
A trial designed to show a new treatment is not meaningfully worse than an active comparator, within a predefined acceptable margin.
Source: Piaggio et al. 2006
What is a non-inferiority trial?
A non-inferiority trial is a trial designed to show that a new treatment is not meaningfully worse than an active comparator, within a predefined acceptable margin, rather than to show it is better. It is used when a new treatment is expected to be similar in effect but to offer other advantages, such as fewer side effects, lower cost, or easier administration, so demonstrating it is not worse by more than a tolerable amount is sufficient. Non-inferiority trials require a well-justified margin and careful conduct to give a credible conclusion.
Source: Piaggio et al. 2006
What does a non-inferiority trial set out to show about a new treatment?
A non-inferiority trial sets out to show that a new treatment is not meaningfully worse than an existing one, rather than that it is better. This is worthwhile when the new option offers other advantages, such as fewer side effects, lower cost, or easier use, and matching the established treatment's effectiveness would be enough to justify it. Success means the new treatment stays within a prespecified margin of the comparator, close enough to count as no worse. Proving it does not fall behind is its aim. Piaggio and colleagues (2006) describe this design.
Source: Piaggio et al. 2006
How does a non-inferiority trial work?
A non-inferiority trial works by defining in advance a non-inferiority margin, the largest amount by which the new treatment could be worse than the comparator while still being acceptable, and then testing whether the confidence interval for the difference excludes a difference worse than that margin. If the new treatment's effect is shown to be no worse than the comparator by more than the margin, non-inferiority is concluded. Unlike an equivalence trial, it uses a one-sided margin, allowing the new treatment to be better, and it requires an effective active comparator.
Source: Piaggio et al. 2006
Why are non-inferiority trials used?
Non-inferiority trials are used when a new treatment is not expected to be more effective than an existing one but offers other benefits, such as better safety, tolerability, convenience, or lower cost, so showing it is not meaningfully worse in effect is enough to support its use. A superiority trial would be inappropriate if no greater effect is expected, and withholding an effective treatment for a placebo comparison may be unethical. So non-inferiority trials allow new treatments with practical advantages to be evaluated against effective standards, provided they are not unacceptably less effective.
Source: Friedman, Furberg & DeMets 2015
Why is the non-inferiority margin important?
The non-inferiority margin is important because it defines how much worse the new treatment may be while still being considered acceptable, and the conclusion of non-inferiority depends entirely on the difference not exceeding it, so the margin must be justified as clinically acceptable and preserve a meaningful fraction of the comparator's known benefit. Too wide a margin could allow an inferior treatment to be accepted. Because the margin determines the validity and meaning of the conclusion, it is specified in advance with clinical and statistical justification, often referencing the comparator's established effect.
Source: Piaggio et al. 2006
What are the challenges of non-inferiority trials?
The challenges of non-inferiority trials include justifying an appropriate margin, which is critical and requires assurance that the comparator's benefit is preserved; the need for high trial quality, since poor conduct, non-adherence, or an ineffective comparator can spuriously make treatments look similar and favour a false non-inferiority conclusion; and the appropriate use of both intention-to-treat and per-protocol analyses, since intention-to-treat can be less conservative here. These challenges mean non-inferiority trials require a well-justified margin, rigorous conduct, an effective comparator, and careful analysis and reporting for a credible conclusion.
Source: Piaggio et al. 2006
Trust Record
Verified by Dr Darrin Baines
British health economist
Professional identity: darrinbaines.org
Verification date: 17 Nov 2025
Content version: 1.0.0
Canonical Identity
- Term code
- HE-ES-CTM-056
Stable URI · Machine-readable · Resolvable · CC BY 4.0